Employing its deep understanding of G-protein coupled receptors (GPCRs) the Beacon Discovery team has delivered more than 20 compounds into clinical development over the past two decades ...

GPCRs are the targets for around one third of all approved drugs 1. Yet such medicines act on only a handful of the 800+ known GPCRs. A wave of biomedical progress in the early 21 st century ...

The poster presentations will highlight Domain’s progress in leveraging GPCR-targeting therapies to modulate the tumor microenvironment and enhance anti-cancer immune responses. DT-7012 – A ...